--- title: "BUZZ-Street View: How Pfizer makes up for patent expiries is key" type: "News" locale: "en" url: "https://longbridge.com/en/news/304274351.md" datetime: "2026-11-04T12:21:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304274351.md) - [en](https://longbridge.com/en/news/304274351.md) - [zh-HK](https://longbridge.com/zh-HK/news/304274351.md) generator: "portal-rs" --- # BUZZ-Street View: How Pfizer makes up for patent expiries is key Pfizer (PFE.N) raised its full-year profit and revenue forecasts on Tuesday as demand for its cancer drug Padcev and blood thinner Eliquis led to higher-than-expected Q3 results 30 analysts rate Pfizer “hold” on average; median PT $29- LSEG-compiled data ### PIPELINE OVER CLIFFSIDE Morgan Stanley (“equal weight,” PT: $26) focused on pipeline execution, which it sees as key to replacing revenue lost from upcoming patent expirations Citigroup (“neutral,” PT: $30) remains confident in co’s dividend, but would not chase stock without better visibility beyond 2027-2029 patent-expiry period and further late-stage pipeline progress Morningstar (Fair Value: $32) sees potential for Pfizer to stand out in obesity market with once-monthly treatment option, though success will depend on tolerability Jefferies (“buy,” PT: $36) says co’s plans for all-oral treatment portfolio for hormone receptor-positive breast cancer could be important as drug Ibrance approaches loss of exclusivity ### Related Stocks - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) ## Related News & Research - [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md) - [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md) - [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md) - [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md) - [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**